The Quigley Corporation Receives U.S. Patent For Its Topical Pain Relief Treatment Of Diabetic Neuropathy

DOYLESTOWN, PA - June 12, 2003 - The Quigley Corporation (Nasdaq: QGLY), www.quigleyco.com, a leading developer and marketer of diversified health products, today announced that it has received a patent for its topical pain relief treatment of diabetic neuropathy. The U.S. Patent, No. 6,555,573 entitled Method and Composition for the Topical Treatment of Diabetic Neuropathy, extends through March 27th 2021.

The patent provides broad protection over Quigley's compound QR-333, which was developed for the treatment of diabetic neuropathy, a condition that will effect a significant percentage of diabetics in their lifetime. Diabetes afflicts 15.7 million people in the United States, according to data compiled from 1995-1998 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),

The Quigley Corporation recently announced the results of its Phase II proof of concept study for compound QR-333. The study concluded that subjects taking QR-333 had 67% of their symptoms improve, strongly suggesting efficacy. Based upon the proof of concept results, Quigley is preparing an IND for submission to the FDA to obtain permission to study and develop the formula as a prescription drug.

"The issuance of the patent for QR-333 is a key milestone for our company and confirms the significance of our drug discovery initiatives. We remain committed to bringing important medical treatments to market and generating future growth," said Guy Quigley, President and CEO of the Quigley Corporation.

Dr. Richard Rosenbloom, inventor of the compound and Executive Vice President and Chief Operations Officer of Quigley Pharma Inc., the wholly owned ethical pharmaceutical subsidiary of the Quigley Corporation stated, "This patent validates the company's pioneering work and vision in developing naturally-derived compounds designed to treat conditions that have not been successfully addressed. We will now seek to develop this compound into a safe and effective commercial prescription drug."

The QR-333 compound is the first in a series of potential drug targets for Quigley Pharma. In addition to QR-333, Quigley has patent applications for compounds to treat sialorrhea (drooling) in patients suffering from Amyotrophic Lateral Sclerosis (ALS), otherwise known as Lou Gehrig's Disease, radiation dermatitis, influenza A and B, herpes and psoriasis/eczema.

No claims are made for the compounds discussed herein are safe, effective, or approved by the federal Food and Drug Administration (FDA).

About The Quigley Corporation
(Nasdaq: QGLY) is a leading developer and marketer of diversified health products including the COLD-EEZE® family of patented Zinc Gluconate Glycine (ZIGG^TM) lozenges, gums and sugar free tablets. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (http://www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. Additional information about The Quigley Corporation is available on its Web site at www.quigleyco.com.

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.